Drug recall · February 5, 2025
Inflectra recall
Why: cGMP Deviations: Product intended for quarantine was inadvertently distributed.
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Inflectra (infliximab-dyyb), For injection, 100mg per vial, packaged in 10 mL single-dose vial, Rx only, Mfd by: CELLTRION, INC, Dist. by: Pfizer Labs, Division of Pfizer Inc., New York, NY 10001, NDC 0069-0809-01
- Lots / codes
Lot# 04647349, Exp Date 5/31/2029
- Quantity
- 192 vials
- Company
- McKesson, Irving, TX
- Distribution
- Nationwide USA
- Initiated
- January 17, 2025 · Voluntary: Firm initiated
- Classified
- January 30, 2025
- Reported
- February 5, 2025
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Infliximab
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.